Please provide your email address to receive an email when new articles are posted on . The proportion of patients with facial acne that reached IGA 0/1 increased from 13.5% to 48.9% after 9 months of ...
Please provide your email address to receive an email when new articles are posted on . The photopneumatic device improved acne in 66.7% of patients in this 7-week trial. Improvements were seen across ...
Xyngari met all three primary endpoints in the STAR-1 Phase 3 trial, showing a statistically significant improvement in acne severity. Dermata plans to start the STAR-2 Phase 3 trial for Xyngari in H2 ...
- Over 30 million acne patients seek treatment in the U.S. each year - - XYNGARI™ Phase 3 STAR-1 trial enrolled 520 patients with moderate-to-severe acne in the U.S. and Latin America- SAN DIEGO, ...
- About 550 patients will be treated once weekly for 12 weeks -- STAR-1 topline results expected in first quarter of 2025 -- Acne affects about 50 million patients in the U.S.- "Getting the first ...
SAN DIEGO, CA / ACCESSWIRE / November 16, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment ...
PARIS — Oral treatment with the novel fatty acid synthase inhibitor denifanstat was associated with significant improvements in moderate-to-severe acne in a phase 3 trial presented at the European ...
– Over 30 million acne patients seek treatment in the U.S. each year – – XYNGARI™ Phase 3 STAR-1 trial enrolled 520 patients with moderate-to-severe acne in the U.S. “We wish to thank the patients and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results